

Original Research Article

Agreement between observers for Pap smear and visual inspection tests

in Florianópolis, southern Brazil

Abstract

Aim: Despite well established validity and reliability of Pap test, a significant proportion of false negative test results still remains and is partially due to the lack of agreement between observers. Visual inspection tests (VIT) share this difficulty but their results are immediately available, thus making it easier to reduce disagreement between observers if these are well trained. The objective of this paper was to verify the agreement on atypical squamous cells of undetermined significance (ASC-US) or higher grade lesions between different examiners with Pap smear and visual inspection tests (VIT) in screening for cervical cancer.

Study design: a cross-sectional study was conducted among consenting clients attending cervical cancer screening services at a non-governmental medical facility in southern Brazil.

Place and Duration of Study: “Rede Feminina de Combate ao Câncer”, a female cancer prevention center in Florianópolis, southern Brazil, between June 2010 and July 2012.

Methodology: Two observers evaluated 353 Pap smear test specimen and 284 visual inspection tests (VIT) of the women screened for cervical cancer in female cancer prevention center in southern Brazil. VIT started with naked eye examination after

Comment [MP1]: The title of this article implies that the agreement between results of Pap and VIT will be the main analysis presented in this article, which is not the case. This would better be titled something such as ‘Comparison of results and agreement between observers of Pap and VIT in southern Brazil: a cross-sectional study’

Comment [MP2]: Does this mean the results of clients’ Pap was compared to the results of the VIT conducted by two observers? As written, it is not clear.

23 visual inspection by applying acetic acid (VIA) and Lugol's iodine (VILI) to
 24 cervix, followed by additional examination with 2x magnifying glass for both modalities.

25 **Results:** Concordance between the first and the second observer regarding Pap test was
 26 reasonably good ($\kappa=0.67$) but was even better regarding all VIT modalities (κ
 27 range 0.76-0.83). Magnifying glass did not significantly improve the
 28 agreement. **Conclusions:** VIT showed very good agreement between observers. Adding
 29 VIT to Pap smear test may improve diagnostic accuracy in cervical cancer screening.

30

31 **Key words:** interobserver agreement, Pap test, visual inspection tests, cervical cancer.

32

Comment [MP3]: So, the two observers were only for the VIT?

Comment [MP4]: Is this concordance between Pap and all VIT modalities? Or concordance between VIA and VILI? Was Pap considered a gold standard?

Comment [MP5]: VIT may have shown good agreement, but did it appear to be highly sensitive / specific compared to a gold standard?

Comment [MP6]: Are the authors suggesting that VIT should be conducted concurrently with Pap?

1 Introduction

Many countries rely solely on the Pap smear test for cervical cancer screening. In Brazil, the National Institute for Cancer (abbrev. INCA in Portuguese) recommends its use for screening women between 25 and 64 years old every three years after two consecutive negative test results [1,2]. However, various errors can occur, such as those during the specimen collection and those due to different interpretations of the specimen between the examiners, as well as false negative test results [3]. This paper examines the second component and describes an attempt to reduce it by adding visual inspection tests (VIT).

Visual inspection techniques (VIT) have been amply piloted in Asian and African countries with limited resources where the access to Pap test screening is too restricted and women health prevention programs are precarious [4-7]. Visual inspection with acetic acid (VIA) and visual inspection with Lugol's iodine (VILI) have been particularly popular among VIT. Their advantages include a sensitivity similar to Pap test in detecting high-grade cervical lesions, low cost, simple execution, availability of test result immediately after the test application and thus the viability of the "see and treat" protocol [5-7]. Also, a short training course of 3-14 days can be administered to medical professionals of varying background in order to capacitate them for cervical screening. VIT are alternative screening methods which are both effective and appropriate in countries with lacking adequate laboratory facilities and well trained screening professionals [6] e.g. Brazil. However, intensive initial training and periodic refreshment and/or upgrade courses are necessary to ensure effectiveness of this strategy in reducing false negative and false positive test results [8,9].

Although interobserver agreement is an important component of diagnostic accuracy, there are very few studies on agreement between health professionals

Comment [MP7]: This contradicts the above which emphasizes the ease of training

involved in cervical cancer screening with VIT, thus limiting the wider application of this method, particularly in the countries with limited resources.

The aim of this study was to verify the interobserver agreement (IOA) in screening for cervical cancer by Pap test and VIT in Florianópolis, southern Brazil.

62

2 Materials and methods

A cross-sectional study evaluated IOA for 353 Pap smear test specimen and 284 VIT specimen of the women who already had sexual relationships and attended cervical cancer screening in Florianópolis, the capital of the Santa Catarina state in southern Brazil, between June 2010 and June 2012. The site was a clinic specialized in this type of screening and maintained by a non-governmental organization set to prevent cancer in women (abbrev. RFCCF in Portuguese).

2.1 Inclusion criteria

All women who were scheduled for regular screening and signed the consent form were eligible for the study providing they had an intact cervix.

2.2 Exclusion criteria

The women who had been submitted to total hysterectomy or diagnosed with HPV, anal or genital condyloma lesions, as well as those diagnosed with HIV, were excluded from the study. Among 353 women screened with Pap test, 96 were not evaluated with VIT because they missed colposcopy scheduled shortly after the Pap test.

2.3 Diagnostic criteria and specimen collection for Pap test

Comment [MP8]: I do not think the lack of studies on IOA for VIT is a limitation to application of its use for screening. Please review Grosskurth, Sanghvi, Limphapayom, Plotkin and Goldie for better grounding in applications in developing countries

Comment [MP9]: Why were you interested in verifying IOA between Pap and VIT? So as to facilitate introduction of use of both Pap and VIT in tandem or to explore feasibility of using VIT instead of Pap?

Comment [MP10]: VIT results were compared, not specimen

Comment [MP11]: If this was not a screening criteria, then just stick to age

Comment [MP12]: Age?

The Pap test specimen was collected by a nurse with over 20 years of work experience. Two specimens were collected for each woman: one by scraping with Ayre spatula from ectocervix and another by endocervical brush from endocervix. Both specimens were fixed by 70% alcohol and stained by Papanicolaou technique.

The Pap test results were classified according to the Bethesda System of 2001 [10]: negative for intraepithelial lesion or malignancy; atypical squamous cells of undetermined significance (ASC-US) or cannot exclude HSIL (ASC-H); Low grade squamous intraepithelial lesion (LSIL); High grade squamous intraepithelial lesion (HSIL) or with features suspicious for invasion (if invasion is suspected); Squamous cell carcinoma; Atypical endocervical cells (not otherwise specified (NOS) or specify in comments), endometrial cells (NOS or specify in comments) and glandular cells (NOS or specify in comments); atypical glandular cells (AGC), AGC-favor neoplastic; endocervical adenocarcinoma in situ; Adenocarcinoma (endocervical, endometrial, extrauterine, not otherwise specified (NOS); other malignant neoplasms.

The first observer to make the diagnosis was a laboratory technician specialized in cytological tests with thirty years of work experience. The second observer was a pathologist specialized in cytopathology and employed by the University Hospital of the Federal University of Santa Catarina for forty years. Both observers had to classify specimen as altered (thus requiring further investigation) or otherwise, where the alteration of interest was defined as atypical squamous cells of undetermined significance (ASC-US) or higher grade. In the case the two observers disagreed, a third observer was called to decide. The latter was a pathologist specialized in cytopathology with over thirty years of work experience and employed by the same laboratory as the second observer. The first observer has access to the medical records standardized by the Brazilian Ministry of Health but did not know whether the

specimen under evaluation was part of the study or not. Both the second and the third pathologist had over thirty years of experience in cervical screening and worked in the same laboratory but did not have access to the medical records nor the knowledge of the first observer's diagnosis.

2.4 Diagnostic criteria and procedures for VIT

VIT were performed by the same nurse who collected the Pap test specimen. She took a 130 hours course on VIT, based on IARC (International Agency for Research on Cancer) manual [11] and administered by an experienced gynecologist specialized in colposcopy and cervical cancer screening. The VIT started immediately after collection of Pap and in the presence of a 100 W cold light with the application of a 5% acetic acid to the cervix for one minute and a naked eye examination to make the VIA diagnosis. Next, a 2% Lugol's iodine solution was applied in order to make the VILI diagnosis. Both VIA and VILI naked eye examinations were followed by additional examination with 2x magnifying glass in order to make VIAM and VILIM diagnoses. The second VIT observer was a gynecologist who re-examined all study participants but was blind to the findings of the first one. In addition, colposcopy was performed for all of them. All VIT results were classified as positive or negative according to the IARC manual [11].

Both VIA and VIAM diagnoses were classified as negative under following conditions after the application of acetic acid: in the absence of acetowhite areas or if these were pale or ill-defined, whitish with undiscernible margins blending with the epithelium, areas with salient white line underlying the squamo-columnar junction (SCJ), angular acetowhite areas, dispersed white areas far away from the SCJ or in the external orifice of the cervix (EOC) if the SCJ was not visualized, acetowhiteness of the mucus

or Nabothian cysts and normal acetowhitening in the columnar epithelium. Positive diagnosis was defined when the visible presence of well-defined, opaque acetowhite areas abutting a fully visible SCJ or the transformation zone or around EOC if SCJ was not visible, as well as acetowhiteness of the entire cervix or its growth [11].

Negative VILI and VILIM diagnoses included the following findings: normal cervix where squamous epithelium turned black or brown and the columnar epithelium remained pale, colorless or partially brown in the transformation zone, or thin yellow, ill-defined non-iodine uptake areas on the cervix located far away from the SCJ, with or without extension to the vagina. Positive diagnosis was defined as well defined, thick, mustard or saffron yellow area touching the SCJ or occupying a large portion of the cervix [11].

Biopsy was performed for all VIT-positive cases, including white acetic epithelium, mosaic or point-like forms, atypical vascular presentations, enlarged glandular orifices and iodine-negative areas. Differently from the IARC manual, the cases considered difficult to classify as either positive or negative on VIT screening were treated as positive and investigated further, thus increasing the possibility of false positive test results.

Individual clinical and laboratory data were entered and analyzed by Stata software version 12.1. Kappa statistic was used to measure agreement between observers. The type I error was fixed at 5% ($P < 0.05$).

2.5 Ethical approval

The Federal University of Santa Catarina ethics committee approved the study protocol under number 681/10 on February 26, 2010.

Comment [MP13]: Analysis is not clear. Pap agreement scores will be compared to Pap and VIT will be compared to VIT, but how were they compared to each other given that they have different output measures? Or were they compared to each other?

3 Results

Mean age of the women who participated in the study was 31.6 years (range 18.0-54.0) for Pap and 29.8 years (range 18.0-53.0) for VIT. The age of the menarche for Pap was reported at 13.0 years (range 10.0-16.0) and that of the first sexual intercourse was at 16.6 years (range 13.0-23.0). For VIT the age of the menarche was reported at 12.7 years (range 10.0-16.0) and that of the first sexual intercourse was at 16.9 years (range 13.0-23.0). Thus the mean age and the age of the menarche was very similar between the women screened by Pap test and by VIT.

Concordance of 0.67 between the first and the second observer regarding Pap test was reasonably good (Table 1). However, concordance indices between these two observers and the third one were poor (kappa values of 0.14 and 0.23).

Comment [MP14]: Can this sentence state what is considered to be high, low, reasonably good range of kappa values?

Table 1– Interobserver agreement for Pap test: kappa statistic and its 95% confidence intervals (CI)

Pap Test	Observer 2		Kappa CI 95%	Observer 3		Kappa CI 95%
	(+)	(-)		(+)	(-)	
Observer 1						
(+)	33	17	0.67 (0.56-0.78)	12	6	0.14 (0.0-0.45)
(-)	10	293		10	9	
Total	43	310		22	15	
Observer 2						
(+)	-	-		18	9	0.23 (0.0-0.54)
(-)	-	-		4	6	
Total				22	15	

Pap test positive (+) if lesion grade $\geq$ ASC-US, otherwise negative (-)

Concordance between the first and the second observer regarding VIT was pretty good for all modalities considered separately as well as pulled together, with kappa values ranging between 0.76 and 0.83 (Table 2).

Table 2– Interobserver agreement for visual inspection tests: kappa statistic and its 95% confidence intervals (CI)

Test	Observer 2		Kappa	Test	Observer 2		Kappa
	(+)	(-)	CI 95%		(+)	(-)	CI 95%
VIA				VIAM			
Observer 1			0.77	Observer 1			0.77
(+)	66	23	(0.65-0.88)	(+)	67	22	(0.65-0.88)
(-)	4	191		(-)	5	190	
Total	70	214		Total	72	212	
VILI				VILIM			
Observer 1			0.81	Observer 1			0.83
(+)	71	22	(0.70-0.93)	(+)	69	20	(0.71-0.94)
(-)	0	191		(-)	0	195	
Total	71	213		Total	69	215	
VIT							
Observer 1			0.76				
(+)	155	4	(0.64-0.87)				
(-)	30	95					
Total	185	99					

VIA = visual inspection with acetic acid;
 VIAM = visual inspection with acetic acid magnified;
 VILI = visual inspection with lugol's iodine;
 VILIM = visual inspection with lugol's iodine magnified;
 VIT = visual inspection tests;
 VIT (+) = any positive results on VIA, VIAM, VILI or VILIM;
 VIT (-) = VIA, VIAM, VILI and VILIM all negative.

Interobserver concordance was low between Pap test and histological examination as gold standard and resulted in high proportion of false negative results of the specimen Pap-diagnosed as normal or inflammatory. Among the former, 32.1% were cervical intraepithelial neoplasia grade 1 (CIN1) and 17.9% were in fact CIN 2 or CIN 3, whereas 32.4% of the cases Pap-diagnosed as inflammatory were considered CIN 1

Comment [MP15]: The Methods section does not make clear that there is a gold standard for Pap. The use of a gold standard should be clarified much earlier.

and 2.7% CIN 2 or CIN 3 by histological examination (Table 3). Three quarters of the

ASC-US and half of the ASC-H diagnoses via Pap test turned out to be CIN 1.

Table 3 Concordance between Pap test and VIT results with histological examination as gold standard

Histopathology Results									
CO Results	Cervicitis and/or Metaplasia		CIN 1		CIN 2/3		Carcinoma		
	Total	n	%	n	%	n	%	n	%
Normal	28	14	50,0	9	32,1	5	17,9	0	0,0
Inflammatory	37	24	64,9	12	32,4	1	2,7	0	0,0
ASC-US	8	2	25,0	6	75,0	0	0	0	0,0
ASC-H	6	1	16,7	3	50,0	1	16,7	1	16,7
LSIL	7	1	14,3	3	42,9	3	42,9	0	0,0
HSIL	7	1	14,3	1	14,3	5	71,4	0	0,0
VIT									
Negative	15	7	46,7	5	33,3	3	20,0	0	0,0
Positive	78	36	46,2	29	37,2	12	15,4	1	1,2
Total	93	43	46,2	34	36,6	15	16,1	1	1,1

ASC-US = atypical squamous cells of undetermined significance;

ASC-H = atypical squamous cells of undetermined significance cannot exclude HSIL ;

LSIL = Low grade squamous intraepithelial lesion ;

HSIL = High grade squamous intraepithelial lesion;

CIN 1 = cervical intraepithelial neoplasia grade 1 ;

CIN 2/3 =cervical intraepithelial neoplasia grade 2 or 3;

VIT (+) = any positive results on VIA, VIAM, VILI or VILIM;

VIT (-) = VIA, VIAM, VILI and VILIM all negatives.

Within Pap-diagnosed LSIL category, 42.9% were diagnosed as CIN 1 and the same percentage as CIN 2 or CIN 3 by histological examination. Within Pap-diagnosed HSIL category, 71.4% were in agreement with the gold standard.

Among VIT-positive cases, 53.8% were confirmed as such by the gold standard, of which 37.2% were CIN 1, 15.4% were CIN 2 or CIN 3 and 1.2% were cancer cases (Table 3). On the other hand, among 15 VIT-negative cases, 46.7% were confirmed as such by the gold standard, one third were diagnosed as CIN 1 and one fifth as CIN 2 or CIN 3.

4 Discussion

Interobserver agreement is an important component of diagnostic accuracy of both Pap and VIT tests. Adequate training of health professionals for cervical cancer screening plays a key role in achieving good accuracy of these tests, particularly in reducing the false negative rate, as reported in another Brazilian study [12].

A reasonable agreement between the first and the second observer regarding Pap test result, and their poor agreement with the third observer, may be explained by inadequate staining and/or fixation of the specimen as reported occasionally by the former. Low quality of the staining material, high workload for the screening professionals and different classification standards for morphological alteration used by the observers may have contributed to disagreement on Pap test diagnoses in some cases. However, it should be kept in mind that the third observer re-examined only the specimen with discrepant diagnosis between the first and the second observer, which were likely more difficult to classify and therefore to agree upon.

Despite above obstacles, the concordance between the first two observers in the present study ($\kappa=0.67$) was better than the one reported in another study based on hundred specimen which were initially evaluated by an experienced laboratory technician and revised by three pathologists, achieving mean κ value of 0.56 [13]. Yet another Brazilian study also found good agreement between the first two observers ($\kappa=0.67$) but their poor agreement with the third one ($\kappa=0.02$) [14]. The concordance between the first observer and an expert panel was pretty good ($\kappa=0.75$), thus indicating a good diagnostic accuracy of the first observer. A lack of precise guidelines for diagnostic interpretation of Pap test contributed to only modest agreement ($\kappa=0.46$) in an important multicentric study which concluded that better training and more rigorous quality control may improve the agreement level [15]. The present study range of κ values (0.76-0.83) confirm this conclusion regarding VIT. Extensive training of the observers with particular attention to the difficulties in diagnostic classification has been emphasized in the literature [5,7-9,16,17] but its routine implementation among screening professionals remains a challenge.

Small magnification (2x) did not improve the IOA of either VIA or VILI in the present study. However, the studies with larger magnification (4x) showed its beneficial effect on diagnostic accuracy, especially in improving test specificity [18].

VILI and VILIM had the highest IOA rates, probably due to the fact that the diagnoses were made immediately after the Lugol's iodine application as opposed to a one minute wait for VIA. In addition, the whitening of acetic acid in VIA may be difficult to localize when the area of lesion is small, within transformation zone, next to a large area of immature metaplasia or glandular tissue. Also, acetic acid may occasionally cause bleeding of the cervix which interferes with accurate VIT diagnosis [19].

Comment [MP16]: Among VIT?

A large multicentric study in India and Africa achieved moderate IOA for VIA, with mean kappa value of 0.38 (range 0.15-0.65) across 11 sites [20]. Considerably higher kappa of 0.77 for VIA in the present study may be due to longer training of the observers and lesser specimen variation in a single center study. The same type of study in Karnataka, India, found low-to-moderate agreement (kappa=0.36) between a nurse and a physician after a 2-week training to diagnose CIN2 or higher grade lesion by VIA, using IARC diagnostic criteria [21]. In the view of these results, it seems worth providing a more extensive training for screening professionals in order to improve IOA with VIT.

Average kappa of 0.57 was obtained for IOA among three VIA experts who evaluated 144 photographs of the cervix after application of acetic acid, without any aid from the clinical data [22]. The women who participated in the study were from India, South Africa and Peru. The results indicate potential of VIA for controlling the quality of screening programs at an affordable cost, even in the countries with limited resources. Where there is a substantial lack of trained screening professionals, nurses can be trained to perform the screening. However, the effectiveness of the training critically depends on its periodic reinforcement, mainly in order to reduce false positive test results and consequently the screening costs [21]. Internet may provide a low-cost alternative to sending digitalized photographs of the cervix to a quality control center. Monitoring whether local screening site has achieved reasonable IOA (kappa 0.40 or higher) can be used among criteria of a good quality cervical cancer prevention [7].

The importance of adequate specimen collection of the transformation zone has been well established in the literature [3,23-25] and confirmed in Table 3 of the present study. This finding goes along with the report that 80% of pre-malignant and malignant cervical lesions originated from SCJ and thus difficult to reach, so that the lesions are

Comment [MP17]: Improving IOA, in the long run, is really about having health care professionals who make good diagnoses. It would be good if that link could be made in the Discussion. Good IOA is just a step closer towards the outcome of better diagnoses since providers do not work in tandem at CaCx screening.

not well represented in the specimen [27]. Some studies have shown that even after very careful specimen collection, less than 20% of the cells collected actually reach the lamina (so-called transference error) and that the specimen collection instruments may be source of error as well [24,25].

A case-control study found that blood and inflammation of the cervix significantly contribute to diagnostic errors in Pap screening [26]. Also, false negative results were highly influenced by the presence of atypical cells, either isolated or in small number, and chromatin. In addition, reinforcing the motivation of screening professionals and periodic refreshment courses may reduce diagnostic errors [6,9,27]. Other factors that reduce diagnostic accuracy are the difficulties in visualizing endocervix and the lack of experience in recognizing adenocarcinoma [11,28].

5 Conclusions

IOA for VIT was very good in the present study as indicated by the kappa range between 0.77 and 0.83 for VIA, VIAM, VILI and VILIM. Magnifying (2x) did not improve the IOA.

IOA was better for VIT than for Pap test, although the difference did not reach statistical significance.

The results of this study give support to the notion that better standardization of the VIT diagnostic criteria, extensive training of screening professionals followed by periodic update and quality control monitoring of screening sites hold promise of significantly improving cervical cancer screening. Nevertheless, more studies are needed to better evaluate the VIT validity and reliability before recommending these

Comment [MP18]: No, the study results do not at all address the training or the programmatic support needed to maintain a high IOA.

306 methods for parallel screening with or as substitution for the Pap test in the countries
307 with limited resources.

Comment [MP19]: This study deserves a better statement of what is needed in terms of programmatic application. 'More studies needed' is not specific enough. The present study has demonstrated that VIT had acceptable comparable results to Pap. Are you recommending that facilities in Brazil introduce studies around using both Pap and VIT? Or introduction of VIT alone? The Discussion has presented adequate results on the validity and reliability of VIT that more studies on that are not needed. Instead, the authors recommendation on how the findings could be applied in the Brazilian setting are needed.

References

1. Brazilian Ministry of Health. National Cancer Institute estimates for the year 2014. Rio de Janeiro: INCA; 2014. Accessed May 5 2014. Available: <http://www.inca.gov.br/estimativa/2014/estimativa-24042014.pdf>.
2. Brazilian Ministry of Health. National Cancer Institute guidelines for cervical cancer screening. In: Chapter 1 - Screening for precursor lesions of cervical cancer. Rio de Janeiro: National Cancer Institute; 2011. Accessed December 10 2013. Available: http://www1.inca.gov.br/inca/Arquivos/Diretrizes_rastreamento_cancer_colo_utero.pdf.
3. World Health Organization-WHO. Cytology Screening in Middle-income Countries. In: Cervical cancer screening in developing countries: report of a WHO consultation. Geneva, Switzerland; 2002. Accessed July 18 2014. Available: <http://whqlibdoc.who.int/publications/2002/9241545720.pdf>.
4. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings clinical benefits and cost-effectiveness. JAMA. 2001;285(24):3107-15.
5. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine. 2006;24(Suppl 3):71-7.
6. Sankaranarayanan R, Nessa A, Esmy PO, Dangou J-M. Visual inspection methods for cervical cancer prevention. Best Pract and Res Clin Obstet Gynecol. 2012;26(2):221-32.
7. World Health Organization-WHO. Visual Inspection with Acetic Acid Application (VIA) as an Alternative Approach to Cytology Screening in Low-Income Countries. In: Cervical cancer screening in developing countries: report of a WHO consultation. Geneva, Switzerland; 2002. Accessed Aug 10 2014. Available: <http://whqlibdoc.who.int/publications/2002/9241545720.pdf>.
8. Sherigar B, Dalal A, Durdi G, Pujar Y, Dhumale H. Cervical cancer screening by visual inspection with acetic acid-interobserver variability between nurse and physician. Asian Pacific J Cancer Prev. 2010;11(3):619-22.
9. Ngoma T, Muwonge R, Mwaiselage J, Kawegere J, Bukori P, Sankaranarayanan R. Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania. Int J Gynecol Obstet. 2010;109(2):100-4.

10. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–19.
11. Sankaranarayanan R, Wesley RS. A practical manual on visual screening for cervical neoplasia. Lyon: IARC Press, pp1-35, 2003. Accessed June 25 2012. Available: <http://screening.iarc.fr/doc/viavilimanual.pdf>.
12. Russo E, Kupek E. Parallel screening with Papanicolaou smear and visual inspection tests significantly reduced false negative screening results in southern Brazil. Br J Med Med Res. 2014;4(14):2783-95.
13. Alli PM, Ollayos CW, Thompson LD, Kapadia I, Butler DR, Williams BH, et al. Telecytology: intraobserver and interobserver reproducibility in the diagnosis of cervical- vaginal smears. Human Pathol. 2001;32(12):1318–22.
14. Santos ALF, Derchain S, Calvert E, Martins M, Duflath R, Martinez E. Performance of cervical cytology with review by different observers and hybrid capture II for the diagnosis of cervical intraepithelial neoplasia grades 2 and 3. Cad Saúde Pública. 2003;19(4):1029–37.
15. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285(11):1500–5.
16. Sankaranarayanan R, Shastri SS, Basu P, Mahé C, Mandal R, Amin G et al. The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia. Cancer Detect and Prev. 2004;28:345–51.
17. Muwonge R, Manuel MDG, Filipe AP, Dumas JB, Frank MR, Sankaranarayanan R. Visual screening for early detection of cervical neoplasia in Angola. Int J Gynecol Obstet. 2010;111(1):68–72.
18. Sritipsukho P, Thaweekul Y. Accuracy of visual inspection with acetic acid (VIA) for cervical cancer screening: a systematic review. J Med Assoc Thai. 2010;93Suppl 7:254–61.
19. Bomfim-Hyppólito S, Franco ES, Franco RGDMM, De Albuquerque CM, Nunes GC. Cervicography as an adjunctive test to visual inspection with acetic acid in cervical cancer detection screening. Int J Gynecol Obstet. 2006;92(1):58–63.

20. Sankaranarayanan R, Basu P, Wesley R, Maché C, et al. Accuracy of visual screening for cervical neoplasia: results from IARC multicentric study in India and Africa. *Int J Cancer*. 2004;110:907-13.
21. Sherigar B, Dalal A, Durdi G, Pujar Y, Dhumale H. Cervical cancer screening by visual inspection with acetic acid-interobserver variability between nurse and physician. *Asian Pacific J Cancer Prev*. 2010;11 (3):619–22.
22. Sellors JW, Jeronimo J, Sankaranarayanan R, Wright TC, Howard M, Blumenthal PD. Assessment of the cervix after acetic acid wash: inter-rater agreement using photographs. *Obstet Gynecol*. 2002;99 (4): 635–40.
23. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention Volume10: Cervix Cancer Screening. Chapter 6: Summary of data. Lyon: IARC Press; 2005. Accessed May 4, 2013. Available: <http://iarc.fr/en/publications/pdfs-online/prev/handbook10/handbook-chap6.pdf..>
24. Queiroz C. False negative test results in cervical cytology: their causes and how to avoid such results. *Femina*. 2001;29(4):211–7.
25. Alves ALL, Almeida GM, Melo VH. The quality of colposcopically guided specimen collection for cytological screening of cervical cancer. *Femina*. 2002;30(3):157–62.
26. Franco R, Amaral RG, Montemor EBL, Montis DM, Morais SS, Zeferino LC. Factores associated with false negative test results in cervical cytopathology. *Rev Bras Ginecol Obstet*. 2006;28(19):479–85.
27. Santos ML, Moreno MS, Pereira VM. Papanicolaou smear test: the quality of specimen collected by the nurse course students. *Rev Bras Cancerol*. 2009;55(1):19–25.
28. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. *Int J Gynecol Obstet*. 2005;89:4–12.